Assistant Clinical Professor, Division of Hematology/Oncology, Medicine
School of Medicine

Staff Physician, Hematology and Oncology, Department of Medicine, VA Long Beach Healthcare System

Lymphoma, Environmental carcinogens

Dartmouth International Health Fellowship 2011
Gold Humanism Society 2013-present
Young Scholars in General Internal Medicine 2017
NIH Loan Repayment Program Award 2019-2020
UCI Department of Medicine Chair’s Research Grant 9/2020-present
Society of Hematologic Oncology:
Young Investigator Program Grant 3/2021

Ma H, Marchi E, O’Connor OA. Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL). Semin Hematol. 2021 Apr;58(2):95-102. PMID: 33906727.

Falchi L, Ma H (contributed equally), Klein S, Lue JK, Marchi E, Deng C, Kim HA, Rada A, Jacob A, Kinahan C, Francescone M, Soderquist CR, Park D, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov A, O’Connor OA. Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study. Blood. 2021 Apr 22;137(16):2161-2170. PMID: 33171487.

Amengual JE, Lue JK, Ma H, Lichtenstein R, Shah B, Cremers S, Jones S, Sawas A. First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma. Oncologist. 2021 Mar;26(3):184-e366. PMID: 33458921.

Ma H, Soderquist CR, Marchi E, Scotto L, Bhagat G, O’Connor OA. A survey of cancer testis antigen (CTA) expression across T-cell lymphoma subtypes. Hematol Oncol. 2020 Dec;38(5):827-830. PMID: 32744349.

Sawas A, Ma H, Kuruvilla J, Lue JK, Deng C, Marchi E, Montanari F, Cheng B, Savage KJ, Villa D, Crump M, Connors JM, O’Connor OA. Prolonged Progression Free Survival in a Subset of Responders to the Combination of Brentuximab Vedotin and Bendamustine in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma: Updated results from an International Multi-Center Phase I/II Experience. Leuk Lymphoma. 2020 Dec;61(12):3014-3017. PMID: 32720828.

Scotto L, Kinahan C, Casadei B, Mangone M, Douglas E, Murty V, Marchi E, Ma H, Deng C, Montanari F, Califano A, O’Connor OA. Generation of Pralatrexate Resistant T-Cell Lymphoma Lines Reveals Two Patterns of Acquired Drug Resistance That Is Overcome with Epigenetic Modifiers. Genes, Chromosomes, and Cancer. 2020 Nov;59(11):639-651. PMID: 32614991.

Ma H, Marchi E, O’Connor OA. The peripheral T-cell lymphomas: An unusual path to cure. Lancet Haematology. 2020 Oct;7(10):e765-e771. PMID 32976753.

Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, O’Connor OA, Sawas A. Low Dose Continuous (LDC) Lenalidomide in Heavily Pretreated Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Retrospective Case Series. Ther Adv Hematol. 2020 Sept;11:2040620720947340. PMID: 33062232.

Sawas A, Ma H, Shustov A, Hsu P, Acosta M, Horwitz S, O’Connor OA. Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2020 Aug;61(8):2003-2007. PMID: 32336176.

Ma H, Cheng B, Falchi L, Marchi E, Bhagat G, O’Connor OA. Novel Therapies and Clinical Trials Prolong Survival in Patients with Peripheral T-cell Lymphomas (PTCL): A Single Institution Retrospective Analysis. Hematol Oncol 2020 Feb;38(1):51-58. PMID: 31872891.

Ayers E, Li S, Medeiros L, Bond D, Maddocks K, Torka P, Mier Hicks A, Curry M, Wagner-Johnston N, Karmali R, Behdad A, Fakhri B, Kahl B, Churnetski M, Cohen J, Reddy N, Modi D, Ramchandern R, Howlett C, Leslie L, Cytryn S, Diefenbach C, Faramand R, Chavez J, Olszewski A, Liu Y, Barta S, Mukhija D, Hill B, Ma H, Amengual J, Nathan S, Assouline S, Orellana-Noia V, Portell C, Chandar A, David K, Giri A, Hess B, Landsburg D. Outcomes in Aggressive B-cell Non-Hodgkin Lymphoma Patients Following Intensive Front-Line Treatment Failure. Cancer 2020 Jan;126(2):293-303. PMID: 31568564.

Ma H, Bhagat G, O'Connor OA. A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: Efficacy of pralatrexate in primary refractory disease and review of the literature. Leuk Lymphoma 2019 Dec;60(13):3300-3303. PMID: 31184235.

Ma H, O'Connor OA, Marchi E. New directions in treating peripheral T-cell lymphomas (PTCL): Leveraging epigenetic modifiers alone and in combination. Expert Rev Hematol 2019 Mar;12(3):137-146. PMID: 30782038.

Ma H and Sawas A. Combining biology and chemistry for a new take on chemotherapy: Antibody drug conjugates in hematologic malignancies. Curr Hematol Malig 2018;13(6):555-569. PMID: 30362019.

Ma H, Davarifar A, Amengual JE. The future of combination therapies for peripheral T cell lymphoma (PTCL). Curr Hematol Malig Rep 2018;13(1):13-24. PMID: 29397528.

Parker S, Zipursky J, Ma H, Baumblatt GL, and Siegel C. A web-based multimedia program prior to colonoscopy increased knowledge and decreased anxiety, sedation requirement, and procedure time. J Clin Gastroenterol 2018;52(6):519-523. PMID: 29095417.

Lin RJ, Ma H, Guo R, Troxel AB, and Diefenbach CS. Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities. Br J Haematol 2018;180(2):267-270. PMID: 29143301.

Ma H and Abdul-Hay M. T-cell lymphomas, a challenging disease: Types, treatments and future. Int J Clin Oncol 2017;22(1):18-51. PMID: 27743148.

American Society of Clinical Oncology (ASCO)

American Society of Hematology (ASH)

American Association for Cancer Research (AACR)

Southwest Oncology Group (SWOG)

Society of Hematologic Oncology (SOHO)

Medical Oncology Association of Southern California (MOASC)

Internal Medicine Primary Care Residency
New York University Medical Center

Hematology and Oncology Fellowship
Columbia University Medical Center

Chao Family Comprehensive Cancer Center

Link to this profile
https://faculty.uci.edu/profile/?facultyId=7034

Last updated
10/16/2021